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Fat-1 miceOmega-3 polyunsaturated fatty acids (n-3 PUFA) have been implicated in the alleviation of asthma. Recent
studies have demonstrated that the n-3 PUFA derived lipidmediators, protectin D1 and resolvin E1, may act as
potent resolution agonists in airway inﬂammation. The effects of the n-3 PUFA tissue status itself on asthma
pathogenesis remains to be further investigated. In this study allergic airway inﬂammation induced by
allergen sensitization and aerosol challenge in Fat-1 and wild-type mice was investigated. Fat-1 transgenic
mice displayed increased endogenous lung n-3 PUFA.When allergen-sensitized and aerosol-challenged, these
animals had decreased airway inﬂammation with decreased leukocyte accumulation in bronchoalveolar
lavage ﬂuid and lung parenchyma. The Fat-1mice had a shift to the right in the dose–response relationship for
methacholine induced bronchoconstriction with a signiﬁcant increase in the log ED200. The Fat-1 mice had
lower BALF concentrations of the pro-inﬂammatory cytokines IL-1α, IL-2, IL-5, IL-9, IL-13, G-CSF, KC and
RANTES. Furthermore, increased lung tissue amounts of the counter-regulatory mediators protectin D1 and
resolvin E1were found in Fat-1mice after bronchoprovocative challenge. These results therefore demonstrate
a direct protective role for lung n-3 PUFA in allergic airway responses and an increased generation of protectin
D1 and resolvin E1 in this context.ospital, 149-13th Street, Room
509; fax: +1 617 726 6144.
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Asthma is a disorder of the airways characterized by airﬂow
obstruction, bronchial hyperresponsiveness, and chronic inﬂamma-
tion accompanied by eosinophil and T-cell inﬁltration in the lungs [1].
The incidence and prevalence of asthma have been increasing in the
last decades and there is no treatment currently available that can
cure asthma.
Lipid mediators derived from omega-6 (n-6) and omega-3 (n-3)
polyunsaturated fatty acids (PUFA) are important regulators of
inﬂammation and may play key roles in the pathogenesis of asthma.
Studies have indicated potent pro-phlogistic roles for the n-6 arachi-
donic acid (AA) derived lipid mediators in asthmatic airways. Pro-
inﬂammatory cytokines and lipid mediators, such as 5-lipoxygenasederived leukotrienes correlate with asthma disease severity [2];
however, lipoxygenases do not only metabolize AA, but also metabolize
the n-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic
acid (EPA) to generate bioactive mediators [3]. Protectins and Resolvins
are pro-resolving mediators that are enzymatically derived from n-3
PUFA. Protectins and Resolvins of the D-series are formed from DHA,
while resolvins of the E-series are derived from EPA [4]. Protectin D1
(PD1) and Resolvin E1 (RvE1) were previously shown to have potent
anti-inﬂammatory and pro-resolving effects [5–7], including in the
airway [8,9]. PD1 is present in exhaled breath condensates of healthy
and asthmatic individuals, and decreases in those suffering an acute
asthma exacerbation [8].
Studies involving Greenland Inuit populations, who have a diet
high in n-3 PUFA due to the intake of marine oils from cold water ﬁsh,
have demonstrated an extremely low incidence of asthma [10].
Further epidemiological studies have conﬁrmed that diets rich in n-3
PUFA are associated with a lower asthma prevalence [11]. In an even
more direct line of evidence for the protective effect of n-3 PUFA in the
context of airway inﬂammation, DHA was found to be protective in
chronic airway inﬂammation when administered endobronchially
[8,12]. However, a recent meta-study failed to conﬁrm a deﬁnitive
protective effect of n-3 PUFA supplementation in asthma [13].
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Fig. 1. Content of EPA and DHA is increased in the lung tissue of Fat-1mice. The n-3 PUFA content in lung tissue, as demonstrated by gas chromatography, was lower inWTmice (A) than
in Fat-1 mice (B). The retention time for EPA and DHA is indicated. The chromatographs are representative of n=11 in each cohort.
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confounding factors of diet or conversion of the parent n-6 and n-3
PUFA to multiple bioactive compounds with competing actions. A
well-controlled model for increased n-3 PUFA tissue status, which
would eliminate confounding factors of diet, would provide an
experimental window onto the effects of increased tissue n-3 PUFA
on asthmatic airway inﬂammation.
In this study, we used transgenic Fat-1 mice as a model of
increased n-3 tissue status to test the effect of increased EPA and DHA
tissue levels on the development of allergen-induced allergic airway
inﬂammation. Fat-1 transgenic mice express a Caenorhabditis elegans
desaturase (Fat-1 gene), leading to the endogenous formation of n-3
PUFA from n-6 PUFA. Due to this capability, Fat-1 mice have a higher
tissue content of n-3 PUFA compared to WT littermates [14], and
increased anti-inﬂammatory effects in models of mucosal organ
injury, including acute lung injury, chemically induced colitis,
hepatitis, and pancreatitis [15–18]. In colitis, endogenous formation
of biologically relevant concentrations of resolvins and protectins
were detected in the colons of Fat-1 mice rich in n-3 PUFA [16]. Here,
the Fat-1 mouse model was used to directly assess the effects of n-3
PUFA on allergic airway responses in a mouse model of asthma.2. Methods
2.1. Mice
Transgenic Fat-1 mice were created as described previously [14].
Heterozygous Fat-1male miceweremated withwild type (WT) female
mice to obtain offspring, with half being heterozygous Fat-1 mice and
half beingWT littermates. Animals were fed a special diet (10% corn oil)
high in n-6 and low in n-3 fatty acids. Tail tissue fatty acid proﬁles were
used for pre-experimental phenotyping of the animals.Table 1
Content of EPA and DHA is increased in the lung tissue of Fat-1 mice.
ng/mg AA EPA DHA AA/(EPA+DHA)
mean±SEM
WT (n=11) 1287.4±191.8 5.2±5.2 197.7±33.2 6.3
Fat-1 (n=11) 1074.4±79.3 146.7±29.9 520.4±54.8 1.6
t-Test 0.317 b 0.001 b 0.00012.2. Induction of allergic airway inﬂammation
For induction of allergic airway inﬂammation, 6–8 weeks old male
Fat-1 and WT mice were injected intraperitoneally with 10 mg
ovalbumin (Sigma, St. Louis, MO) plus 1 mg aluminium hydroxide
as adjuvant in 0.2 ml normal saline on days 0 and 7 of the protocol,
essentially as described previously [9]. On days 14, 15, 16 and 17, mice
received aerosol challenges with 6% (wt/vol) OVA in PBS for 25 min
per day. Mice were sacriﬁced on protocol day 18 to analyze lipid
proﬁles of the lungs and the extent of airway inﬂammation.2.3. Bronchoalveolar lavage preparation and cell counts
Bronchoalveolar lavage ﬂuid (BALF) was collected using PBS with
0.6 mMEDTA (2 x 1 ml). The ﬂuids and tissues collectedwere used for
cytological and histological analysis as well as biochemical measure-
ments. Cells were stained with a Wright–Giemsa stain (Sigma) to
quantify leukocyte subsets and ≥200 cells were counted on each
slide. As controls, two animals in each group with vehicle-only i.p.
injection and PBS-only inhalation were added. The supernatants of
BALF samples were analyzed for the presence of cytokines using a 23-
panel of murine cytokine/chemokines in a Multiplex Suspension
Array System (Bio-Rad, Hercules, CA).
2.4. Measurement of lung resistance
For measurement of airway hyperresponsiveness, anesthetized
miceweremechanically ventilatedwith a ﬂexiVent (SciReq, Chandler,
AZ) and aerosolizedmethacholine (0, 1, 3, 10, 30 and 100 mg/ml) was
delivered in-line through the inhalation port for 10 s. Airway
resistance was determined as the mean of ten measurements
obtained for each concentration of methacholine and is reported as
the percent increase from baseline (PBS nebulization).
2.5. Analysis of polyunsaturated fatty acids and lipid mediators
Fatty acid proﬁles were analyzed by using gas chromatography as
described previously using a fully automated HP6890 system
equipped with a ﬂame-ionization detector [19]. Peaks of resolved
fatty acids were identiﬁed by comparison with fatty acid standards
(NuChek Prep, Elysian, MN). Resolvin (Rv) E1 and protectin D1 (PD1)
was analyzed by liquid chromatography–tandem mass spectrometry,
essentially as described previously [15]. In short, the supernatant of a
lung tissue homogenate in acetonitrile with d4-PGE2 as internal
standard was dried under nitrogen, resuspended in 5 mM ammonium
acetate in water, and injected into a Linear Ion Trap Quadrupole
LC/MS/MS Mass Spectrometer.
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Fig. 2. Decreased airway inﬂammation and mucus metaplasia in Fat-1 transgenic mice. Lung tissue from WT (left) and Fat-1 (right) mice was obtained and prepared for
histopathological analysis (see Methods). (A, B) Lung sections stained with H & E revealed decreased leukocyte inﬁltration and less reactive airway epithelium in the lungs of Fat-1
mice compared toWT littermate controls. (C, D) Periodic Acid-Schiff staining revealed decreasedmucus (arrows) in the airway epithelium in Fat-1mice as compared toWT controls.
Images are representative for n=3 in each cohort.
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For data analysis Prism 5.00 software (GraphPad, San Diego, CA)
was used. Comparison was made by using the Student t-test and one-
way ANOVA. All values are presented as the mean±SEM or as
indicated. Level of signiﬁcance was set at pb0.05.Fig. 3. Fat-1 mice exhibit decreased airwayWBC in allergic inﬂammation. Bronchoalveolar la
challenges (see Methods). (A) Total BALF cells were enumerated and WBC differential coun
each cohort), *pb0.05.3. Results
3.1. Expression of the Fat-1 transgene increases lung tissue n-3 PUFA
To determine the impact of Fat-1 expression on lung PUFA levels,
lung tissue from Fat-1 and WT animals used in this study wasvage was performed on OVA sensitized animals 24 h after the last of 4 daily OVA aerosol
ts were performed manually after Cytospin and Wright–Giemsa stain (B–E). (n=6 for
Fig. 4. Methacholine-induced airway hyperresponsiveness is decreased in fat-1 mice.
(A) Airway hyper-responsiveness to methacholine was determined using amouse
ventilator with in-line nebulizer (see Methods). (A) Mean lung resistance (R) was
measured at baseline and after each dose of methacholine. R was signiﬁcantly
decreased in Fat-1 relative to WT mice. (B) The effective dose of methacholine needed
to increase mean lung resistance by 200% from baseline (ED200) was signiﬁcantly
higher for Fat-1 compared to WT mice. Values represent the mean±SEM for n=6WT
and n=5 Fat-1 mice. *pb0.05.
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fatty acid composition indicated that the amounts of the n-3 PUFA EPA
(C20:5n-3) and DHA (C22:6n-3) in fat-1 heterozygote mice were
signiﬁcantly higher and levels of the n-6 PUFA AA trended to be lower
in Fat-1 transgenic mice than in WT littermates (Fig. 1 and Table 1),
leading to a marked decrease in the AA/(EPA+DHA) ratio from 6.3 to
1.6 (***pb0.001). These ﬁndings indicate that expression of Fat-1
effectively increased n-3 PUFA levels in lung tissue, resulting in a
signiﬁcant difference in lung fatty acid composition between Fat-1
and WT littermates despite the same diet for both groups.3.2. Allergic airway Inﬂammation is decreased in Fat-1 transgenic mice
To determine the impact of endogenous n-3 PUFA on the
development of allergic airway inﬂammation, Fat-1 transgenic mice
and their littermate WT controls were systemically sensitized to OVA
and then aerosol challenged for 25 min with 6% OVA on 4 consecutive
days (see Methods). Twenty-four hours after the last allergen
challenge, lungs were prepared for histopathological analyses.
Samples from Fat-1 transgenic mice displayed markedly fewer
leukocytes and the airway epithelium was less reactive than in WT
animals that were also OVA sensitized and challenged (Fig. 2A, B).
Periodic Acid-Schiff staining revealed decreased mucus metaplasia of
airway epithelium in the Fat-1 compared to littermate WT control
mice (Fig. 2C, D). In lieu of lung harvest for histology, some animals
underwent bronchoalveolar lavage (BAL) 24 h after the last allergen
challenge. BAL ﬂuids (BALF) from the Fat-1 mice revealed a marked
decrease in total cells as compared toWTmice (n=6 for Fat-1 as well
as WT mice), and leukocyte differential counts in these samples
demonstrated signiﬁcant decrements in BALF eosinophils (9.8±
2.5×105 in WT versus 2.3±0.9×105 in Fat-1, pb0.05), the differ-
ences for lymphocytes (5.5±1.7×104 in WT versus 2.1±0.6×104 in
Fat-1) and macrophages (4.0±1.1×105 in WT versus 1.8±0.2×105
in Fat-1) did not reach statistical signiﬁcance at this sample size
(Fig. 3). These results indicate that increased lung levels of n-3 PUFA
were associated with a dramatic decrease in the development of
allergic airway inﬂammation.3.3. Fat-1 mice are protected from methacholine-induced
airway hyperresponsiveness
In addition to airway inﬂammation, airway hyper-responsiveness
(AHR) is another diagnostic hallmark of asthma. To determine the
impact of n-3 PUFA on AHR, animals were anesthetized, mechanically
ventilated and bronchoprovocation challenge was performed (ﬂexi-
Vent, SciREQ)with inhaledmethacholine at escalating doses from 1 to
100 mg/ml. Similar to the changes in airway inﬂammation, Fat-1 mice
displayed a signiﬁcant dampening of methacholine-induced increases
in lung mean resistance (R) with a shift in the dose response
relationship to the right (Fig. 4A). The effective dose of methacholine
leading to a 200% increase in lung mean resistance (ED200) was
signiﬁcantly increased in Fat-1 transgenic mice (Fig. 4B).
3.4. BALF cytokine and chemokine levels are decreased in Fat-1 mice
To determine mechanisms for the observed effect on allergic
airway responses in Fat-1 mice, BALF aliquots were analyzed using a
protein bead array for cytokines and chemokines. There were
signiﬁcant decrements in the levels of several pro-inﬂammatory
mediators in Fat-1 mice, including IL-1α, IL-2, IL-5, IL-13, G-CSF, KC
(CXCL1) and RANTES (CCL5) (Fig. 5). In addition, there were
concomitant decreases in IL-1β, IL-3, IL-10, IL-12 (p40), IL-17, INF-γ,
MCP-1, MIP-1α, MIP-1β and TNF-α in the Fat-1 mice, but these trends
did not reach statistical signiﬁcance at this sample size (data not
shown). Of interest, IL-9 was detectable only in BALF fromWT animals
but not in samples from Fat-1 mice (Fig. 5). None of the peptide
mediators that were assayed were increased in the Fat-1 mice, but
levels of IL-12(p70), IL-17 and GM-CSF were essentially unaltered.
3.5. Lipid mediator proﬁle
To determine the impact of the increased n-3 PUFA on RvE1 and
PD1, lung tissue homogenates were subjected to solid phase
extraction and then materials were analyzed by LC-MS/MS. Because
of limited availability of fat-1 mice, murine lungs were harvested after
bronchoprovocative testing with methacholine. There was a marked
difference in lung tissue levels of both RvE1 and PD1 between Fat-1
and WT mice. Both RvE1 and PD1 were detectable in WT lung after
methacholine challenge (Fig. 6).
4. Discussion
In the present study, we used the Fat-1mousemodel to investigate
the effect of increased tissue status of n-3 PUFA on allergic airway
responses. Our results demonstrate that endogenously increased lung
n-3 PUFA decreases allergic airway inﬂammation with reduced
leukocyte inﬁltration and inﬂammatory cytokine and chemokine
levels, and also suppresses airway hyper-responsiveness to metha-
choline, whichwas associatedwith an increase in formation of the n-3
PUFA derived pro-resolving mediators RvE1 and PD1.
One key objective of this study was to address the potential impact
of tissue status of n-6 and n-3 PUFA on allergic airway inﬂammation.
We utilized a genetic approach instead of traditional dietary
supplementation to modify the n-6 and n-3 PUFA content in lung
tissue by expression of the Fat-1 gene, which led to endogenous
conversion of n-6 to n-3 fatty acids. Use of this approach can not only
signiﬁcantly increase tissue n-3 content, but can also decrease n-6
content, resulting in a large difference in lung tissue n-6/n-3 fatty acid
ratio between Fat-1 andWTmice. The tissue content of n-3 PUFAmay
be critical in airway inﬂammation as previous studies observed the
presence of DHA in human airway mucosa and decreases in the
setting of airway inﬂammation in asthma and cystic ﬁbrosis [20].
n-3 PUFAs are important precursors for anti-inﬂammatory and
pro-resolving mediators [4], so this study focused on RvE1 and PD1.
Fig. 5. Select cytokine and chemokine levels were lower in BALF from Fat-1 mice. BALF was analyzed for cytokines and chemokines using a Multiplex Suspension Array System (Bio-
Rad). Values represent the mean±SEM for n=5 WT and n=6 Fat-1 mice. *pb0.05 n.d., not detected.
Fig. 6. Formation of n-3 PUFA derived lipid mediators in Fat-1 mice was increased.
There were signiﬁcant increases in the formation of resolvin E1 (RvE1, A) and protectin
D1 (PD1, B) in lung tissue from methacholine treated animals (***pb0.001, **pb0.01).
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protectins have potent anti-inﬂammatory and pro-resolution effects
[7], in particular in the lung [8,9]. Levels of RvE1 and PD1 were 6–
8 times higher in the lungs of Fat-1 transgenic mice than those of WT
littermates and in the pg to ng range. Systemic administration of 2 to
200 ng of PD1 or RvE1 is pharmacologically active in this model [8,9],
consistent with a potent regulatory activity for these amounts of RvE1
and PD1 in this model. PD1 and its biosynthetic precursor, 17-
hydroxy-DHA, are present in murine lung and human exhaled breath
condensates [8]. In inﬂamedmurine lung, levels of RvE1 are below the
limits of detection, but here RvE1 could be detected after methacho-
line challenge. These ﬁndings point to the rapid formation and
metabolism of RvE1, a potent locally acting autacoid.
Given the importance of cytokines and chemokines in airway
inﬂammation in asthma, their content and composition in the BAL
ﬂuids were analyzed. The results suggest that the increased n-3 PUFA
preferentially modulate the Th2-cell response, as in Fat-1 mice there
was a marked down-regulation of IL-5, IL-9, IL-13 and RANTES, which
are chemokines and cytokines that are integral to Th2 driven immune
1169S. Bilal et al. / Biochimica et Biophysica Acta 1812 (2011) 1164–1169responses [21–25]. IL-5 is an eosinophil-speciﬁc colony-stimulating
factor [26] and decrements in this Th2 cytokine correlated well with
our observations of lower eosinophil counts in Fat-1 mice compared
to WT animals.
Our results provide evidence that airway inﬂammation and hyper-
responsiveness can be reduced by changing tissue n-6 PUFA to n-3
PUFA, highlighting the importance of the n-6/n-3 PUFA ratio in
asthma. The increased incidence of asthma inWestern societies can be
attributed in part to the consumption of an n-6-rich pro-inﬂammatory
diet. In a typical Western diet, the ratio of n-6 to n-3 PUFA is 20:1 or
even higher [27]. On this basis, decreasing the tissue n-6/n-3 PUFA
ratio by dietarymeans to both lower n-6 and increase n-3 PUFAwould
be expected to lessen the incidence and severity of asthma. The
decreased inﬂammation observed with a lower n-6/n-3 PUFA ratio
could be partially due to reduced n-6 PUFA-derived lipid mediator
formation as a result of competitive inhibition or down-regulation of
cyclooxogenase/lipoxygenase enzymes. However, the data presented
here point to another important effect, the formation of n-3 PUFA
derived anti-inﬂammatory and pro-resolving mediators.
Increased formation of n-3 PUFA derived anti-inﬂammatory and
pro-resolving mediators by fat-1 mice also suggest the direct
administration of these natural compounds, namely RvE1 and PD1,
as a potential therapeutic intervention for asthma, given their potent
activity in regulating allergic airway responses in model systems. Of
interest, increased PUFA availability does not always translate into
increased formation of protective mediators, as asthma exacerbations
and severe asthma are associated with defects in PD1 and lipoxin A4
generation [8,28].
In conclusion, increasing lung tissue levels of n-3 PUFAmay provide
a protective effect against asthma. One of the underlying mechanisms
for this protection was an increase in enzymatic conversion of EPA and
DHA to pro-resolvingmediators, such as protectins and resolvins. These
ﬁndings address some of the observed health beneﬁts for diets rich in
marine oils, and also point to potentially important roles for tissue n-3
PUFA and the n-6/n-3 PUFA ratio in asthma prevention and treatment.Acknowledgments
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